News & Media

Press Releases

Amolyt Pharma Announces Research Collaboration with PeptiDream

Amolyt Pharma Announces Research Collaboration with PeptiDream Download a PDF copy of this press release: EN FR Amolyt and Peptidream will collaborate to optimize and …

Download a PDF: EN or FR

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed.

Download a PDF: EN or FR

Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced the appointment of Pierre Legault, MBA, CPA as director and chairman of its board of directors…

Download a PDF: EN or FR

Upcoming events

Date: March 20-23, 2021

Learn more about the conference »

Social Updates

TWITTER

Scroll to Top